1. Home
  2. XOMA vs MGTX Comparison

XOMA vs MGTX Comparison

Compare XOMA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMA
  • MGTX
  • Stock Information
  • Founded
  • XOMA N/A
  • MGTX 2015
  • Country
  • XOMA United States
  • MGTX United States
  • Employees
  • XOMA N/A
  • MGTX N/A
  • Industry
  • XOMA Biotechnology: Pharmaceutical Preparations
  • MGTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • XOMA Health Care
  • MGTX Health Care
  • Exchange
  • XOMA Nasdaq
  • MGTX Nasdaq
  • Market Cap
  • XOMA 298.3M
  • MGTX 282.3M
  • IPO Year
  • XOMA N/A
  • MGTX N/A
  • Fundamental
  • Price
  • XOMA $27.00
  • MGTX $4.60
  • Analyst Decision
  • XOMA Strong Buy
  • MGTX Strong Buy
  • Analyst Count
  • XOMA 2
  • MGTX 2
  • Target Price
  • XOMA $57.00
  • MGTX $26.00
  • AVG Volume (30 Days)
  • XOMA 31.1K
  • MGTX 208.8K
  • Earning Date
  • XOMA 08-06-2024
  • MGTX 08-08-2024
  • Dividend Yield
  • XOMA N/A
  • MGTX N/A
  • EPS Growth
  • XOMA N/A
  • MGTX N/A
  • EPS
  • XOMA N/A
  • MGTX N/A
  • Revenue
  • XOMA $5,811,000.00
  • MGTX $697,000.00
  • Revenue This Year
  • XOMA $349.94
  • MGTX N/A
  • Revenue Next Year
  • XOMA $28.50
  • MGTX $447.29
  • P/E Ratio
  • XOMA N/A
  • MGTX N/A
  • Revenue Growth
  • XOMA 73.10
  • MGTX N/A
  • 52 Week Low
  • XOMA $13.48
  • MGTX $3.49
  • 52 Week High
  • XOMA $27.36
  • MGTX $7.60
  • Technical
  • Relative Strength Index (RSI)
  • XOMA 58.66
  • MGTX 56.56
  • Support Level
  • XOMA $24.36
  • MGTX $3.97
  • Resistance Level
  • XOMA $27.10
  • MGTX $4.20
  • Average True Range (ATR)
  • XOMA 1.39
  • MGTX 0.22
  • MACD
  • XOMA 0.27
  • MGTX 0.08
  • Stochastic Oscillator
  • XOMA 98.09
  • MGTX 80.94

About XOMA XOMA Corporation

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Share on Social Networks: